Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Lifts JD HEALTH (06618.HK) TP to $71, Keeps Rating at Outperform
Recommend 4 Positive 5 Negative 0 |
||||
|
||||
|
JD HEALTH (06618.HK)'s 3Q25 results beat expectations in terms of both revenue and profit, CLSA published a research report saying. Total revenue/ adjusted EBIT grew by 29%/ 60% YoY to RMB17.1 billion/ RMB1.4 billion, respectively. Pharmaceutical sales maintained a strong YoY growth of 30%, with originator drugs and chronic disease drugs performing particularly well, while health supplement sales also accelerated to a 30% YoY incline. JD HEALTH continued to maintain a strong advantage through its first-party operating model. The broker raised its 2025/ 2026 adjusted net profit forecasts by 11% each to reflect stronger gross profit margin expansion, and lifted its target price from $66 to $71, with rating kept at Outperform. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
